Asia Pacific Interventional Oncology Device Market Snapshot
The Asia Pacific interventional oncology device market will see strong growth through 2034, driven by updated clinical guidelines, broader access to minimally invasive cancer treatments, and growing physician confidence in ablation and embolization. Adoption of premium-priced devices will be supported by positive clinical trial data, unmet demand in China and India, and changing modality preferences in liver and lung tumor ablation. However, growth will be limited by reimbursement gaps, cost sensitivity, and competition from domestic manufacturers. Additionally, the Chinese interventional oncology device market will go through a shift after the implementation of VBP for these devices.
Read our Market Snapshot to access data and analysis on the state of the market for interventional oncology devices in the Asia Pacific region from 2019 to 2034.